PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
PVCT was delisted on the 13th of October, 2016.
35 hedge funds and large institutions have $3.45M invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2015 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 6 closing their positions.
10% less funds holding
Funds holding: 39 → 35 (-4)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
12% less capital invested
Capital invested by funds: $3.91M → $3.45M (-$464K)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$49.3K |
| 2 |
GW
GW & Wade
Wellesley,
Massachusetts
|
+$24.7K |
| 3 |
Creative Planning
Overland Park,
Kansas
|
+$12.4K |
| 4 |
SGH
Schonfeld Group Holdings
Jericho,
New York
|
+$12.4K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$12K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$309K |
| 2 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$160K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$90.2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$32.9K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$23K |
PVCT Hedge Fund Activity: Q1 2015 in Review
35 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q1 2015, worth a combined $3.45M — down 12% from $3.91M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of PVCT and 2 opened new positions — a net loss of 4 holders — while 9 trimmed existing stakes and 8 added.
The largest buyer was Renaissance Technologies, adding an estimated $49.3K. The largest seller was Virtu KCG Holdings, cutting an estimated $309K.
- 35 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q1 2015, down from 39 in Q4 2014.
- Funds reported $3.45M of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q1 2015, down 12% quarter-over-quarter.
- 2 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q1 2015 and 6 closed out, a net change of -4 holders.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) buyer in Q1 2015 was Renaissance Technologies, an estimated $49.3K added.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q1 2015 was Virtu KCG Holdings, an estimated $309K sold.
Based on aggregated 13F filings for Q1 2015.